share_log

Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024

Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024

Chimerix將於2024年5月1日公佈2024年第一季度財務業績並提供最新運營情況
Chimerix ·  04/24 12:00

DURHAM, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Wednesday, May 1, 2024 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2024, and to provide a business overview.

北卡羅來納州達勒姆,2024年4月24日(GLOBE NEWSWIRE)——以開發有效改善和延長面臨致命疾病的患者壽命的藥物爲使命的生物製藥公司Chimerix(納斯達克股票代碼:CMRX)今天宣佈,它將在美國東部時間2024年5月1日星期三上午8點30分舉辦電話會議和網絡音頻直播,公佈截至3月31日的第一季度財務業績,2024 年,並提供業務概覽。

To access the live conference call, please dial (646) 307-1963 (domestic) or (800) 715-9871 (international) at least five minutes prior to the start time, and refer to conference ID 1246220. A live audio webcast of the call will also be available on the Investors' section of the Company's website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.

要觀看電話會議,請在開始時間前至少五分鐘撥打(646)307-1963(國內)或(800)715-9871(國際),並參考會議編號1246220。本次電話會議的網絡直播也將在公司網站的投資者專區播出, www.chimerix.com。活動結束大約兩小時後,Chimerix網站上將提供存檔的網絡直播。

About Chimerix

關於 Chimerix

Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company's most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.

Chimerix是一家生物製藥公司,其使命是開發能夠有效改善和延長面臨致命疾病的患者壽命的藥物。該公司最先進的臨床階段開發項目 ONC201 正在開發針對 H3 k27M 突變神經膠質瘤。

CONTACT:
Will O'Connor
Stern Investor Relations
212-362-1200
will@sternir.com

聯繫人:
威爾·奧康納
斯特恩投資者關係
212-362-1200
will@sternir.com

Primary Logo

Source: Chimerix, Inc.

來源:Chimerix, Inc.

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論